Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19

NCT04435353 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-06-17

No results posted yet for this study

Summary

Vibroacoustic pulmonary therapy in patients with COVID19 is believed to have a positive effect on oxygen status and a decrease in the duration of respiratory failure

Conditions

  • Respiratory Distress Syndrome
  • Hypoxemia

Interventions

DEVICE

VibroLUNG

Lungs intensive therapy

Sponsors & Collaborators

  • Astana Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-22
Primary Completion
2020-12-31
Completion
2021-02-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435353 on ClinicalTrials.gov